Tobi Solution
Product Images NDC 49502-345

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Tobi (NDC 49502-345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tobramycin Structural Formula (Image 01)

FDA Label Image

Figure 1: Relative Change From Baseline In Fev1% Predicted (Image 02)

Figure 1: Relative Change From Baseline In Fev1% Predicted (Image 02)
This text seems to be a table containing data from four studies: Study 1 and 2 for both TOBI and placebo treatment. The table reports the average relative change in FEV1 % Predicted for each study. The number of participants in each study is also mentioned. There is a reference to "number at baseline" but without more context it is difficult to know what it refers to.*
FDA Label Image

Figure 2: Absolute Change From Baseline In Log10 Cfus (Image 03)

Figure 2: Absolute Change From Baseline In Log10 Cfus (Image 03)
This appears to be a graph or chart showing the average change in logarithmic colony-forming units (CFUs) over time (in weeks) for two studies. The studies are labeled "Study 1" and "Study 2" and have been conducted with both a placebo and a drug called TOBI. However, without further context or more readable data, it is difficult to provide a more specific description or analysis.*
FDA Label Image

Instructions For Use Figure A (Image 04)

FDA Label Image

Instructions For Use Figure B (Image 05)

FDA Label Image

Instructions For Use Figure C (Image 06)

FDA Label Image

Instructions For Use Figure D (Image 07)

FDA Label Image

Instructions For Use Figure E (Image 08)

Instructions For Use Figure E (Image 08)
This text only provides a list of words and does not offer any context or further information. Therefore, a useful description cannot be generated.*
FDA Label Image

Instructions For Use Figure F (Image 09)

FDA Label Image

Instructions For Use Figure G (Image 10)

FDA Label Image

Instructions For Use Figure H (Image 11)

FDA Label Image

Instructions For Use Figure I (Image 12)

FDA Label Image

Instructions For Use Figure J (Image 13)

FDA Label Image

Instructions For Use Figure K (Image 14)

FDA Label Image

Instructions For Use Figure L (Image 15)

FDA Label Image

Instructions For Use Figure M (Image 16)

FDA Label Image

Instructions For Use Figure N (Image 17)

FDA Label Image

Instructions For Use Figure O (Image 18)

FDA Label Image

Instructions For Use Figure P (Image 19)

FDA Label Image

Instructions For Use Figure Q (Image 20)

FDA Label Image

Tobramycin Inhalation Solution Carton Label (Image 21)

Tobramycin Inhalation Solution Carton Label (Image 21)
This text describes the contents, dosage, and administration instructions, and storage recommendations for Tobramycin Inhalation Solution, USP. Each package contains 56 single-use ampules, each containing 300 mg of Tobramycin and 1125 mg of Sodium Chord. The recommended dosage is one single-use ampule twice daily, administered through a nebulizer. Proper storage instructions are provided, and the package should be kept in the refrigerator. The text includes a product code and Rx symbol. However, there is a mix of readable and unreadable characters, and the output seems incomplete and inconsistent, which may make it difficult to understand certain aspects of the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.